Taken together, these studies demonstrate that genetic modification of CD34+ cells using CD11b.SGSH LV fulfills the essential pre-clinical safety and efficacy requirements prior to commencing a phase I-II HSCGT clinical trial in MPSIIIA patients. This evidence concerns the gene CD34 and mucopolysaccharidosis type 3A.